Overview

The marketing authorisation for Nuedexta has been withdrawn at the request of the marketing-authorisation holder.

български (BG) (312.89 KB - PDF)

View

español (ES) (266.25 KB - PDF)

View

čeština (CS) (293.48 KB - PDF)

View

dansk (DA) (266.6 KB - PDF)

View

Deutsch (DE) (267.83 KB - PDF)

View

eesti keel (ET) (269.56 KB - PDF)

View

ελληνικά (EL) (320.31 KB - PDF)

View

français (FR) (267.84 KB - PDF)

View

hrvatski (HR) (283.73 KB - PDF)

View

italiano (IT) (264.25 KB - PDF)

View

latviešu valoda (LV) (302.74 KB - PDF)

View

lietuvių kalba (LT) (283 KB - PDF)

View

magyar (HU) (284.97 KB - PDF)

View

Malti (MT) (290.76 KB - PDF)

View

Nederlands (NL) (264.69 KB - PDF)

View

polski (PL) (284.4 KB - PDF)

View

português (PT) (286.28 KB - PDF)

View

română (RO) (268.86 KB - PDF)

View

slovenčina (SK) (285.42 KB - PDF)

View

slovenščina (SL) (286.75 KB - PDF)

View

Suomi (FI) (262.95 KB - PDF)

View

svenska (SV) (265.02 KB - PDF)

View

Product information

български (BG) (1.24 MB - PDF)

View

español (ES) (638.47 KB - PDF)

View

čeština (CS) (994 KB - PDF)

View

dansk (DA) (630.24 KB - PDF)

View

Deutsch (DE) (690.2 KB - PDF)

View

eesti keel (ET) (627.09 KB - PDF)

View

ελληνικά (EL) (1.36 MB - PDF)

View

français (FR) (691.37 KB - PDF)

View

hrvatski (HR) (642.16 KB - PDF)

View

íslenska (IS) (955.72 KB - PDF)

View

italiano (IT) (651.76 KB - PDF)

View

latviešu valoda (LV) (994.32 KB - PDF)

View

lietuvių kalba (LT) (810.7 KB - PDF)

View

magyar (HU) (994.57 KB - PDF)

View

Malti (MT) (1.04 MB - PDF)

View

Nederlands (NL) (663.87 KB - PDF)

View

norsk (NO) (943.33 KB - PDF)

View

polski (PL) (1.71 MB - PDF)

View

português (PT) (649.06 KB - PDF)

View

română (RO) (655.52 KB - PDF)

View

slovenčina (SK) (976.88 KB - PDF)

View

slovenščina (SL) (925.24 KB - PDF)

View

Suomi (FI) (653.71 KB - PDF)

View

svenska (SV) (642.3 KB - PDF)

View

Latest procedure affecting product information: IAIN/0005

24/10/2014

icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (167.05 KB - PDF)

View

español (ES) (153.71 KB - PDF)

View

čeština (CS) (160.1 KB - PDF)

View

dansk (DA) (154.47 KB - PDF)

View

Deutsch (DE) (154.57 KB - PDF)

View

eesti keel (ET) (153.66 KB - PDF)

View

ελληνικά (EL) (177.22 KB - PDF)

View

français (FR) (153.69 KB - PDF)

View

hrvatski (HR) (282.98 KB - PDF)

View

íslenska (IS) (169.64 KB - PDF)

View

italiano (IT) (152.66 KB - PDF)

View

latviešu valoda (LV) (164.45 KB - PDF)

View

lietuvių kalba (LT) (154.89 KB - PDF)

View

magyar (HU) (160.64 KB - PDF)

View

Malti (MT) (160.78 KB - PDF)

View

Nederlands (NL) (153.75 KB - PDF)

View

norsk (NO) (170.1 KB - PDF)

View

polski (PL) (159.71 KB - PDF)

View

português (PT) (154.08 KB - PDF)

View

română (RO) (153.69 KB - PDF)

View

slovenčina (SK) (159.39 KB - PDF)

View

slovenščina (SL) (157.93 KB - PDF)

View

Suomi (FI) (152.94 KB - PDF)

View

svenska (SV) (136.89 KB - PDF)

View

Product details

Name of medicine
Nuedexta
Active substance
  • dextromethorphan
  • quinidine
International non-proprietary name (INN) or common name
  • dextromethorphan hydrobromide
  • quinidine sulfate
Therapeutic area (MeSH)
Neurobehavioral Manifestations
Anatomical therapeutic chemical (ATC) code
N07XX59

Pharmacotherapeutic group

Other nervous system drugs

Therapeutic indication

Nuedexta is indicated for the symptomatic treatment of pseudobulbar affect (PBA) in adults. Efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.

Authorisation details

EMA product number
EMEA/H/C/002560
Marketing authorisation holder
Jenson Pharmaceutical Services Limited

Carradine House
237 Regents Park Road
London
N3 3LF
United Kingdom

Marketing authorisation issued
24/06/2013
Revision
2

Assessment history

Topics

This page was last updated on

Share this page